Inhalation Sciences’ PreciseInhale in 2018 Best Paper Award for Drug Delivery & Translational Research

Inhalation Sciences’ aerosol generating system PreciseInhale has been named in the winning research paper of the 2018 Drug Delivery and Translational Research Best Paper Award, granted by the influential cross-disciplinary drug delivery research body the CRS (Controlled Release Society).

The Annual Controlled Release Society Awards honour scientists who have contributed outstandingly to delivery science and technology. They are Awarded by the cross-disciplinary research group the CRS. Founded in 1978 as a not-for-profit organisation, CRS members today produce new research into delivery, development, regulatory science and clinical translation that is seen as highly influential in the development of new technologies in the delivery field.

CRS’ 2018 Best Paper Award (‘2018 DRUG DELIVERY AND TRANSLATIONAL RESEARCH BEST PAPER AWARD’) went to Annie Lexmond and the team of scientists at Kings’ College London’s Institute of Pharmaceutical Science, for critical aerosol research they carried out using inhalation Sciences’ PreciseInhale.

ISAB CEO Lena Heffler: “We’re delighted for the team at Kings' for this well-deserved win - and for what it clearly says about PreciseInhale. Precision dosing is moving rapidly from being an option to being a new accepted standard. This Award is further proof of how leading our technology is. The scientists at CRS are without a doubt important thought leaders within drug delivery. Their confirmation is hugely important.”

The paper, “A novel method for studying airway hyperresponsiveness in allergic guinea pigs in vivo using the PreciseInhale system for delivery of dry powder aerosols”, was authored by A. J. Lexmond, S. Keir, W. Terakosolphan, C. P. Page and Professor Ben Forbes.

For more information on Inhalation Sciences, please contact:

Lena Heffler, CEO 
E-mail: lena.heffler@inhalation.se
Telephone: +46 (0)70 205 9620

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we breathe them in.

Taggar:

Om oss

Inhalation Sciences Sweden AB (publ.) utvecklar och kommersialiserar världsledande instrument för forskning inom inhalation. Bolagets patenterade labinstrument, PreciseInhale erbjuder forskare möjligheten att, med mycket hög precision, karakterisera hur aerosoler och små partiklar påverkar våra lungor när vi andas in dem.